BioNTech

NEWS

Policy

Biopharma Update on the Novel Coronavirus: August 21

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.

August 20, 2020

5 min read

BioSpace Editorial Staff

Policy

Biopharma Update on the Novel Coronavirus: August 12

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.

August 11, 2020

5 min read

BioSpace Editorial Staff

BioCapital

Clinical Catch-Up: August 3-7

It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

August 6, 2020

8 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.

August 4, 2020

5 min read

BioSpace Editorial Staff

Business

Regeneron and BioNTech Partner on Immunotherapy Combo for Melanoma

Regeneron Pharmaceuticals and BioNTech have inked a strategic collaboration to combine BioNTech’s BNT111 FixVac product candidate and Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab) for the treatment of melanoma.

August 3, 2020

2 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: July 31

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.

July 30, 2020

4 min read

BioSpace Editorial Staff

BioSpace Global Roundup, July 30

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

July 29, 2020

5 min read

Alex Keown

Policy

Biopharma Update on the Novel Coronavirus: July 29

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.

July 29, 2020

5 min read

BioSpace Editorial Staff

Drug Development

Pfizer and BioNTech Begin Global Phase II/III COVID-19 Vaccine Trial

The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).

July 28, 2020

3 min read

Mark Terry